Deciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefit (NASDAQ:DCPH)

DNA strands

Evgenii Kovalev

Deciphera Pharmaceuticals (NASDAQ:DCPH) is a biopharmaceutical company whose mission is to develop innovative and effective treatments for cancer patients. This goal is facilitated by their focus on drug discovery and development, resulting in a robust pipeline of potential drugs, with



exploratory data

competitor scoring

tgct market

Read more here: Source link